gilead sciences gilead sciences
Stories About

gilead sciences

Gilead Sciences, maker of the antiviral drug remdesivir, has come up with a price for the COVID-19 treatment that was less than some analysts expected. ULRICH PERREY/POOL/AFP via Getty Images hide caption

toggle caption
ULRICH PERREY/POOL/AFP via Getty Images

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

  • Download
  • <iframe src="https://www.npr.org/player/embed/884648842/884958712" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2. Andrew Harnik/AP hide caption

toggle caption
Andrew Harnik/AP

After the Food and Drug Administration granted Gilead Sciences orphan drug status for its experimental drug remdesivir on Tuesday, Gilead asked that the agency rescind that status Wednesday. Bloomberg/Bloomberg via Getty Images hide caption

toggle caption
Bloomberg/Bloomberg via Getty Images